Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -102.65
- Piotroski Score 3.00
- Grade Buy
- Symbol (NRXP)
- Company NRx Pharmaceuticals, Inc.
- Price $1.22
- Changes Percentage (0.83%)
- Change $0.01
- Day Low $1.19
- Day High $1.23
- Year High $7.33
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $5.20
- Trailing P/E Ratio 0.62
- Forward P/E Ratio 0.62
- P/E Growth 0.62
- Net Income $-30,150,000
Income Statement
Quarterly
Annual
Latest News of NRXP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ...
Hope Therapeutics aims to build a national network of precision psychiatry clinics by acquiring clinics specializing in ketamine, TMS, and psychiatric management. Revenue projections are promising wit...
By Yahoo! Finance | 3 days ago
